

ERBB2 Antibody

Purified Mouse Monoclonal Antibody (Mab) Catalog # AM8446b

Product Information

Application	WB, IHC-P, E
Primary Accession	<u>P04626</u>
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Isotype	IgG2b,к
Clone Names	1423CT594.76.52
Calculated MW	137910
Antigen Region	102-339

Additional Information

Gene ID	2064
Other Names	Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, CD340, ERBB2, HER2, MLN19, NEU, NGL
Target/Specificity	This ERBB2 antibody is generated from a mouse immunized with a recombinant protein.
Dilution	WB~~1:1000 IHC-P~~1:1000 E~~Use at an assay dependent concentration.
Format	Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	ERBB2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	ERBB2
Synonyms	HER2, MLN19, NEU, NGL
Function	Protein tyrosine kinase that is part of several cell surface receptor

	complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
Cellular Location	Cell membrane; Single-pass type I membrane protein. Cell projection, ruffle membrane; Single-pass type I membrane protein. Note=Internalized from the cell membrane in response to EGF stimulation. [Isoform 2]: Cytoplasm. Nucleus.
Tissue Location	Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth.

Background

Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.

References

Yamamoto T.,et al.Nature 319:230-234(1986). Coussens L.,et al.Science 230:1132-1139(1985). Wakamatsu A.,et al.Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases. Mural R.J.,et al.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. Tal M.,et al.Mol. Cell. Biol. 7:2597-2601(1987).

Images



Western blot analysis of lysate from MDA-MB-453, SK-BR-3 cell line (from left to right), using ERBB2 Antibody (1423CT594. 76. 52). 1423CT594. 76. 52 was diluted at 1:1000. A goat anti-mouse IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody. Lysate at 20µg per lane.

Immunohistochemical analysis of paraffin-embedded Human Breast cancer section using Pink1(Cat#AM8446b).



AM8446b was diluted at 1:1000 dilution. A undiluted biotinylated goat polyvalent antibody was used as the secondary, followed by DAB staining.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.